These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Primary staging in patients with intermediate- and high-risk prostate cancer: Multiparametric MRI and Skawran SM; Sanchez V; Ghafoor S; Hötker AM; Burger IA; Huellner MW; Eberli D; Donati OF Eur J Radiol; 2022 Jan; 146():110044. PubMed ID: 34844173 [TBL] [Abstract][Full Text] [Related]
12. Comparison of Zamboglou C; Drendel V; Jilg CA; Rischke HC; Beck TI; Schultze-Seemann W; Krauss T; Mix M; Schiller F; Wetterauer U; Werner M; Langer M; Bock M; Meyer PT; Grosu AL Theranostics; 2017; 7(1):228-237. PubMed ID: 28042330 [TBL] [Abstract][Full Text] [Related]
13. Detection and localisation of primary prostate cancer using Kalapara AA; Nzenza T; Pan HYC; Ballok Z; Ramdave S; O'Sullivan R; Ryan A; Cherk M; Hofman MS; Konety BR; Lawrentschuk N; Bolton D; Murphy DG; Grummet JP; Frydenberg M BJU Int; 2020 Jul; 126(1):83-90. PubMed ID: 31260602 [TBL] [Abstract][Full Text] [Related]
14. Draulans C; Pos F; Smeenk RJ; Kerkmeijer L; Vogel WV; Nagarajah J; Janssen M; Mai C; Heijmink S; van der Leest M; Zámecnik P; Oyen R; Isebaert S; Maes F; Joniau S; Kunze-Busch M; De Roover R; Defraene G; van der Heide UA; Goffin K; Haustermans K Pract Radiat Oncol; 2021; 11(3):202-211. PubMed ID: 33941347 [TBL] [Abstract][Full Text] [Related]
15. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
16. [ Xie Y; Li C; Zhang L; Zang S; Yu F; Wang S; Wang F Nan Fang Yi Ke Da Xue Xue Bao; 2022 Aug; 42(8):1143-1148. PubMed ID: 36073212 [TBL] [Abstract][Full Text] [Related]
17. Pilot study of the diagnostic utility of Vlachostergios PJ; Niaz MJ; Thomas C; Christos PJ; Osborne JR; Margolis DJA; Khani F; Bander NH; Scherr DS; Tagawa ST Prostate; 2022 Mar; 82(4):483-492. PubMed ID: 34985786 [TBL] [Abstract][Full Text] [Related]
18. Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI, Akkaya H; Dilek O; Özdemir S; Taş ZA; Öztürk İS; Gülek B Diagn Interv Radiol; 2023 Sep; 29(5):647-655. PubMed ID: 37395389 [TBL] [Abstract][Full Text] [Related]
19. Detection Rate of Pepe P; Pepe L; Cosentino S; Ippolito M; Pennisi M; Fraggetta F Anticancer Res; 2022 Jun; 42(6):3011-3015. PubMed ID: 35641295 [TBL] [Abstract][Full Text] [Related]
20. Diagnostic efficiency of hybrid imaging using PSMA ligands, PET/CT, PET/MRI and MRI in identifying malignant prostate lesions. Scobioala S; Kittel C; Wolters H; Huss S; Elsayad K; Seifert R; Stegger L; Weckesser M; Haverkamp U; Eich HT; Rahbar K Ann Nucl Med; 2021 May; 35(5):628-638. PubMed ID: 33742373 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]